Recent DOJ and DEA actions have advanced federal marijuana policy following President Trump’s December 2025 executive order directing expedited rescheduling to Schedule III. In April 2026, officials issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28, while withdrawing prior proceedings to streamline the process. An expedited administrative hearing on broader rescheduling of all marijuana from Schedule I begins June 29, 2026, with a compressed timeline ending no later than July 15. These steps reflect administration priorities on research access and regulatory consistency, though full implementation for non-medical cannabis depends on the hearing outcome and any subsequent rulemaking or legal challenges.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$762,399 Vol.
31 mar 2026
30 giugno
2%
31 dicembre
26%
$762,399 Vol.
30 giugno
$338,633 Vol.
2%
31 dicembre
$158,884 Vol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent DOJ and DEA actions have advanced federal marijuana policy following President Trump’s December 2025 executive order directing expedited rescheduling to Schedule III. In April 2026, officials issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28, while withdrawing prior proceedings to streamline the process. An expedited administrative hearing on broader rescheduling of all marijuana from Schedule I begins June 29, 2026, with a compressed timeline ending no later than July 15. These steps reflect administration priorities on research access and regulatory consistency, though full implementation for non-medical cannabis depends on the hearing outcome and any subsequent rulemaking or legal challenges.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercato aperto: Feb 7, 2026, 5:04 PM ET
Volume
$762,399Data di fine
31 mar 2026Mercato aperto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent DOJ and DEA actions have advanced federal marijuana policy following President Trump’s December 2025 executive order directing expedited rescheduling to Schedule III. In April 2026, officials issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28, while withdrawing prior proceedings to streamline the process. An expedited administrative hearing on broader rescheduling of all marijuana from Schedule I begins June 29, 2026, with a compressed timeline ending no later than July 15. These steps reflect administration priorities on research access and regulatory consistency, though full implementation for non-medical cannabis depends on the hearing outcome and any subsequent rulemaking or legal challenges.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$762,399Data di fine
31 mar 2026Mercato aperto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent DOJ and DEA actions have advanced federal marijuana policy following President Trump’s December 2025 executive order directing expedited rescheduling to Schedule III. In April 2026, officials issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective April 28, while withdrawing prior proceedings to streamline the process. An expedited administrative hearing on broader rescheduling of all marijuana from Schedule I begins June 29, 2026, with a compressed timeline ending no later than July 15. These steps reflect administration priorities on research access and regulatory consistency, though full implementation for non-medical cannabis depends on the hearing outcome and any subsequent rulemaking or legal challenges.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti